Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. [artículo]
Por: Pulido Ortega, Federico [Unidad VIH]
.
Colaborador(es): Servicio de Medicina Interna.
Editor: The Journal of antimicrobial chemotherapy, 2013Descripción: 68(6):1373-81.Recursos en línea: Solicitar documento Resumen: BACKGROUND: Discontinuation of thymidine nucleoside reverse transcriptase inhibitors (tNRTIs) is the only proven strategy for improving lipoatrophy. It is unclear whether switching to NRTI-sparing or to non-thymidine NRTI-containing therapy has differential effects on body fat recovery.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC8209 (Navegar estantería) | Disponible |
Formato Vancouver:
Bernardino JI, Pulido F, Martínez E, Arrizabalaga J, Domingo P, Portilla J et al. GESIDA-6008-KRETA Study Group. Switching
to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. J Antimicrob Chemother. 2013 Jun;68(6):1373-81.
PMID: 23386261
Contiene 31 referencias
BACKGROUND: Discontinuation of thymidine nucleoside reverse transcriptase inhibitors (tNRTIs) is the only proven strategy for improving lipoatrophy. It is unclear whether switching to NRTI-sparing or to non-thymidine NRTI-containing therapy has differential effects on body fat recovery.
No hay comentarios para este ejemplar.